{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:22:51Z","timestamp":1787696571701,"version":"build-2784847793"},"reference-count":26,"publisher":"Elsevier BV","issue":"14","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:00:00Z","timestamp":1719964800000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.heliyon.2024.e34107","type":"journal-article","created":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T03:55:04Z","timestamp":1720065304000},"page":"e34107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Refractory pruritus caused by sintilimab and its clinical management: A case report"],"prefix":"10.1016","volume":"10","author":[{"given":"Li","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.heliyon.2024.e34107_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CCO.0b013e3282f1c595","article-title":"Neuroendocrine tumors of the diffuse neuroendocrine system","volume":"20","author":"Gustafsson","year":"2008","journal-title":"Curr. Opin. Oncol."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e34107_bib2","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/MCG.0b013e3181d7a6d4","article-title":"Neuroendocrine tumors of the gallbladder: an evaluation and reassessment of management strategy","volume":"44","author":"Eltawil","year":"2010","journal-title":"J. Clin. Gastroenterol."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e34107_bib3","article-title":"Can surgical treatment be justified for neuroendocrine carcinoma of the gallbladder?","volume":"98","author":"You","year":"2019","journal-title":"Medicine (Baltim.)"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e34107_bib4","first-page":"252","article-title":"Research progress of gallbladder neuroendocrine carcinoma","volume":"31","author":"Yongjin","year":"2022","journal-title":"Chin. J. Gen. Surg."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e34107_bib5","first-page":"351","article-title":"A case of nausea, rash, and itching caused by coffee acid tablets","volume":"28","author":"Yilin","year":"2019","journal-title":"Chin. J. Pharmacoepidemiol."},{"issue":"31","key":"10.1016\/j.heliyon.2024.e34107_bib6","first-page":"10+12","article-title":"A case report and clinical analysis of carboplatin-induced anaphylaxis","volume":"4","author":"Lihai","year":"2017","journal-title":"Journal Of Practical Gynecologic Endocrinology"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e34107_bib7","first-page":"568","article-title":"One case of severe drug eruption induced by piperacillin sodium and tazobactam for injection in children","volume":"16","author":"Kouzhu","year":"2019","journal-title":"Chinese Journal of Pharmacovigilance"},{"issue":"64","key":"10.1016\/j.heliyon.2024.e34107_bib8","first-page":"166","article-title":"One case of tumor itching and visual changes caused by etopol","volume":"15","author":"Bo","year":"2015","journal-title":"World lastest medicine information (electronic version)"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e34107_bib15","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"ESMO Guidelines Committee. Electronic address:sManagement of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e34107_bib16","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Society for immunotherapy of cancer toxicity management working group. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the society for immunotherapy of cancer (SITC) toxicity management working group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.heliyon.2024.e34107_bib17","series-title":"The Chinese Society of Clinical Oncology (CSCO): Guidelines for the Toxicity Management Related to Immune Checkpoint Inhibitors","author":"Jie","year":"2021"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e34107_bib9","first-page":"650","article-title":"The role and case analysis of the Norodom assessment scale in the evaluation of adverse drug reactions","volume":"47","author":"Feiyue","year":"2012","journal-title":"Chin. Pharmaceut. J."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e34107_bib10","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/CCO.0000000000000290","article-title":"Dermatologic complications of anti-PD-1\/PD-L1 immune checkpoint antibodies","volume":"28","author":"Sibaud","year":"2016","journal-title":"Curr. Opin. Oncol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e34107_bib11","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor-related dermatologic adverse events","volume":"83","author":"Geisler","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e34107_bib12","first-page":"1229","article-title":"Cutaneous reactions to epidermal growth factor receptor inhibitors","volume":"9","author":"Pomerantz","year":"2010","journal-title":"J. Drugs Dermatol. JDD"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e34107_bib13","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamadermatol.2015.1916","article-title":"Pembrolizumab cutaneous adverse events and their association with disease progression","volume":"151","author":"Sanlorenzo","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e34107_bib14","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/1346-8138.13520","article-title":"Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: a multi-institutional retrospective study","volume":"44","author":"Nakamura","year":"2017","journal-title":"J. Dermatol."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e34107_bib18","first-page":"786","article-title":"Progress of steroids effect on efficacy of immune checkpoint inhibitors","volume":"22","author":"Guoqiang","year":"2019","journal-title":"Chin. J. Lung Cancer"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e34107_bib19","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/ki.2013.454","article-title":"Uremic pruritus","volume":"87","author":"Mettang","year":"2015","journal-title":"Kidney Int."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e34107_bib20","article-title":"Low dose naloxone for pruritus in systemic sclerosis: case series and literature review","volume":"101","author":"Meridor","year":"2022","journal-title":"Medicine (Baltim.)"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e34107_bib21","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/brain\/awaa430","article-title":"Central opioid receptors mediate morphine-induced itch and chronic itch via disinhibition","volume":"144","author":"Wang","year":"2021","journal-title":"Brain"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e34107_bib22","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1111\/j.1468-3083.2010.03850.x","article-title":"Chronic pruritus--pathogenesis, clinical aspects and treatment","volume":"24","author":"Metz","year":"2010","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"16","key":"10.1016\/j.heliyon.2024.e34107_bib23","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1056\/NEJMc1805637","article-title":"PD-1 blockade-induced pruritus treated with a mu-opioid receptor antagonist","volume":"379","author":"Kwatra","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e34107_bib24","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1200\/JOP.18.00797","article-title":"Naloxone and maintenance naltrexone as novel and effective therapies for immunotherapy-induced pruritus: a case report and brief literature review","volume":"15","author":"Singh","year":"2019","journal-title":"J Oncol Pract"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e34107_bib25","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/00003643-200106000-00002","article-title":"Pharmacological control of opioid-induced pruritus: a quantitative systematic review of randomized trials","volume":"18","author":"Kjellberg","year":"2001","journal-title":"Eur. J. Anaesthesiol."},{"issue":"15","key":"10.1016\/j.heliyon.2024.e34107_bib26","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.2146\/ajhp100475","article-title":"Use of pure opioid antagonists for management of opioid-induced pruritus","volume":"68","author":"Miller","year":"2011","journal-title":"Am. J. Health Syst. Pharm."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024101387?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024101387?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T13:30:01Z","timestamp":1773840601000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024101387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":26,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S2405844024101387"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e34107","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Refractory pruritus caused by sintilimab and its clinical management: A case report","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e34107","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e34107"}}